Natera presents new Signatera ctDNA studies at ASTRO, highlighting radiation oncology use cases
NTRA•Natera reported new Signatera clinical data presented at the ASTRO 2026 annual meeting, its first appearance at the conference. Studies found the test flagged patients at higher risk of relapse and supported organ-preservation strategies.
1. Studies presented at ASTRO
Across studies in colorectal and anal cancers, with additional evidence in gynecologic settings, Signatera monitoring flagged patients at higher risk of relapse following chemoradiation or radiotherapy. The data also supported using the test to identify patients more likely to remain disease-free under surveillance.
